Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -1.79%76 3-Year ROIIC % is 155.91 as of Mar. 2026, which is 101% above its 10-year median of 77.60. GuruFocus rates BOM:500126 with a GF Score™ of 76/100 and a GF Value™ of ₹5,780.35 (Fairly Valued). The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, Procter & Gamble Health ranks better than 93.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Procter & Gamble Health's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 155.91%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Procter & Gamble Health's 3-Year ROIIC % or its related term are showing as below:
BOM:500126's 3-Year ROIIC % is ranked better than 93.33% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs BOM:500126: 155.91
Procter & Gamble Health (BOM:500126) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Procter & Gamble Health 3-Year ROIIC % Related Terms
Procter & Gamble Health 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Procter & Gamble Health (BOM:500126) has a 3-Year ROIIC % of 155.91 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Procter & Gamble Health and its competitors. This is 101% above median its historical median of 77.60. According to the industry distribution chart, Procter & Gamble Health ranks #63 out of 944 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is Procter & Gamble Health's 3-Year ROIIC % too high?
Procter & Gamble Health's current 3-Year ROIIC % of 155.91 is 101% above median its 10-year median of 77.60. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Procter & Gamble Health's value of 155.91 is 4218.8% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #63 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #63 out of 944 companies for 3-Year ROIIC %. This places Procter & Gamble Health in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.61. Procter & Gamble Health's value of 155.91 is 4218.8% above this benchmark. While the company's 10-year median is 77.60 vs. the industry median of 3.61, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current 3-Year ROIIC % of 155.91 is 4218.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current 3-Year ROIIC % is 155.91, which is 101% above median its own 10-year median of 77.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,780.35, compared to a current price of ₹5,679.10 — trading 1.8% below its estimated fair value. The current 3-Year ROIIC % is 155.91, which is 101% above median its 10-year median of 77.60 and 4218.8% above the Drug Manufacturers industry median of 3.61. Procter & Gamble Health's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current 3-Year ROIIC % is 155.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹5,679.10 is trading 1.8% below its estimated GF Value™ of ₹5,780.35.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
3-Year ROIIC %: 155.91 (101% above median its 10-year median of 77.60)
GF Value™: ₹5,780.35 vs. price of ₹5,679.10 (1.8% below fair value)
Industry Position: 4218.8% above the Drug Manufacturers median (#63 of 944)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
76GF Score
Get the complete analysis for BOM:500126
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
